Media

News Release 22 March 2024

Actigen’s Managing Director, Michael Braunagel, Panellist at China-UK Rare Disease Symposium

Insights into Actigen’s contribution to advancing global collaboration in tackling rare diseases, from the recent China-UK Rare Disease Symposium in Shanghai.

News Release 28 November 2023

The brave new world of enzyme replacement therapy

Revolutionising rare disease treatment using facilitated transcytosis

News Release 12 September 2023

Back to life (back to reality)

Why we should embrace digital health technology to transform our approach to clinical trials and medicine development

News Release 6 April 2023

Rare diseases: not so rare after all

The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment

Blog 25 January 2023

Taking compounds from clinical to commercial: An investment-led strategy

Our Business Development Lead Kamilla Rolsted discusses her career and the trials and tribulations of securing investment in the competitive and highly niche field of rare disease.

News Release 17 January 2023

Helping Rare Diseases Emerge from the Shadows to Take Centre Stage

Actigen’s Managing Director Michael Braunagel shares his thoughts on how the rare disease treatment market has been transformed in recent years and begun to receive greater industry recognition.

Blog 15 August 2022

From cancer research pioneer to rare disease breakthroughs – Michael’s 30-year journey

Our very own Michael Braunagel takes us through his three-decade-long career spanning three countries, ranging from cutting edge cancer research to developing a potentially groundbreaking clinical treatment in the field of rare diseases.

News Release 12 July 2022

Cambridge Biotech Company Receives Positive FDA Response for Breakthrough Rare Disease Treatment

News Release 21 March 2022

A Cinderella Story: Rethinking Clinical Trials and Rare Diseases

News Release 14 March 2022

Actigen Initiates Development Programme in Rare Disease MPS II